Report Detail
Global CAR-T Therapy for Hematological Cancer Market 2026 by Company, Regions, Type and Application, Forecast to 2032
- RnM4717070 |
- 29 June, 2026 |
- Global |
- 87 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global CAR-T Therapy for Hematological Cancer market size was valued at US$ 6878 million in 2025 and is forecast to a readjusted size of US$ 32990 million by 2032 with a CAGR of 25.4% during review period.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a cutting-edge immunotherapy for hematological cancers, involving the genetic modification of a patient’s T cells to express synthetic receptors targeting specific antigens on cancer cells. These engineered T cells are expanded in the lab and reintroduced into the patient, where they can recognize and destroy cancerous cells with high specificity. Key features include its remarkable efficacy in treating certain blood cancers like B-cell lymphomas, leukemias, and multiple myeloma, particularly in patients with relapsed or refractory disease, and its potential for long-term remission. CAR-T therapy is primarily applied in advanced hematological malignancies and is being explored for broader indications through ongoing clinical trials. Despite its promise, challenges such as high cost, manufacturing complexity, and management of severe side effects like cytokine release syndrome (CRS) remain areas of active research.
This report is a detailed and comprehensive analysis for global CAR-T Therapy for Hematological Cancer market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global CAR-T Therapy for Hematological Cancer market size and forecasts, in consumption value ($ Million), 2021-2032
Global CAR-T Therapy for Hematological Cancer market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global CAR-T Therapy for Hematological Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global CAR-T Therapy for Hematological Cancer market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for CAR-T Therapy for Hematological Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global CAR-T Therapy for Hematological Cancer market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J&J, JW Therapeutics, FOSUNKite, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
CAR-T Therapy for Hematological Cancer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Target: CD19
Target: BCMA
Others
Market segment by Application
Lymphoma
Multiple Myeloma
Leukemia
Market segment by players, this report covers
Novartis
Gilead Sciences
Bristol-Myers Squibb
J&J
JW Therapeutics
FOSUNKite
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe CAR-T Therapy for Hematological Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CAR-T Therapy for Hematological Cancer, with revenue, gross margin, and global market share of CAR-T Therapy for Hematological Cancer from 2021 to 2026.
Chapter 3, the CAR-T Therapy for Hematological Cancer competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and CAR-T Therapy for Hematological Cancer market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of CAR-T Therapy for Hematological Cancer.
Chapter 13, to describe CAR-T Therapy for Hematological Cancer research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of CAR-T Therapy for Hematological Cancer by Type
- 1.3.1 Overview: Global CAR-T Therapy for Hematological Cancer Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global CAR-T Therapy for Hematological Cancer Consumption Value Market Share by Type in 2025
- 1.3.3 Target: CD19
- 1.3.4 Target: BCMA
- 1.3.5 Others
- 1.4 Global CAR-T Therapy for Hematological Cancer Market by Application
- 1.4.1 Overview: Global CAR-T Therapy for Hematological Cancer Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Lymphoma
- 1.4.3 Multiple Myeloma
- 1.4.4 Leukemia
- 1.5 Global CAR-T Therapy for Hematological Cancer Market Size & Forecast
- 1.6 Global CAR-T Therapy for Hematological Cancer Market Size and Forecast by Region
- 1.6.1 Global CAR-T Therapy for Hematological Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 1.6.2 Global CAR-T Therapy for Hematological Cancer Market Size by Region, (2021-2032)
- 1.6.3 North America CAR-T Therapy for Hematological Cancer Market Size and Prospect (2021-2032)
- 1.6.4 Europe CAR-T Therapy for Hematological Cancer Market Size and Prospect (2021-2032)
- 1.6.5 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size and Prospect (2021-2032)
- 1.6.6 South America CAR-T Therapy for Hematological Cancer Market Size and Prospect (2021-2032)
- 1.6.7 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size and Prospect (2021-2032)
2 Company Profiles
- 2.1 Novartis
- 2.1.1 Novartis Details
- 2.1.2 Novartis Major Business
- 2.1.3 Novartis CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.1.4 Novartis CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novartis Recent Developments and Future Plans
- 2.2 Gilead Sciences
- 2.2.1 Gilead Sciences Details
- 2.2.2 Gilead Sciences Major Business
- 2.2.3 Gilead Sciences CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.2.4 Gilead Sciences CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Gilead Sciences Recent Developments and Future Plans
- 2.3 Bristol-Myers Squibb
- 2.3.1 Bristol-Myers Squibb Details
- 2.3.2 Bristol-Myers Squibb Major Business
- 2.3.3 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.3.4 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.4 J&J
- 2.4.1 J&J Details
- 2.4.2 J&J Major Business
- 2.4.3 J&J CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.4.4 J&J CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 J&J Recent Developments and Future Plans
- 2.5 JW Therapeutics
- 2.5.1 JW Therapeutics Details
- 2.5.2 JW Therapeutics Major Business
- 2.5.3 JW Therapeutics CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.5.4 JW Therapeutics CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 JW Therapeutics Recent Developments and Future Plans
- 2.6 FOSUNKite
- 2.6.1 FOSUNKite Details
- 2.6.2 FOSUNKite Major Business
- 2.6.3 FOSUNKite CAR-T Therapy for Hematological Cancer Product and Solutions
- 2.6.4 FOSUNKite CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 FOSUNKite Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global CAR-T Therapy for Hematological Cancer Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of CAR-T Therapy for Hematological Cancer by Company Revenue
- 3.2.2 Top 3 CAR-T Therapy for Hematological Cancer Players Market Share in 2025
- 3.2.3 Top 6 CAR-T Therapy for Hematological Cancer Players Market Share in 2025
- 3.3 CAR-T Therapy for Hematological Cancer Market: Overall Company Footprint Analysis
- 3.3.1 CAR-T Therapy for Hematological Cancer Market: Region Footprint
- 3.3.2 CAR-T Therapy for Hematological Cancer Market: Company Product Type Footprint
- 3.3.3 CAR-T Therapy for Hematological Cancer Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global CAR-T Therapy for Hematological Cancer Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global CAR-T Therapy for Hematological Cancer Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
- 5.1 Global CAR-T Therapy for Hematological Cancer Consumption Value Market Share by Application (2021-2026)
- 5.2 Global CAR-T Therapy for Hematological Cancer Market Forecast by Application (2027-2032)
6 North America
- 6.1 North America CAR-T Therapy for Hematological Cancer Consumption Value by Type (2021-2032)
- 6.2 North America CAR-T Therapy for Hematological Cancer Market Size by Application (2021-2032)
- 6.3 North America CAR-T Therapy for Hematological Cancer Market Size by Country
- 6.3.1 North America CAR-T Therapy for Hematological Cancer Consumption Value by Country (2021-2032)
- 6.3.2 United States CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 6.3.3 Canada CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 6.3.4 Mexico CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
7 Europe
- 7.1 Europe CAR-T Therapy for Hematological Cancer Consumption Value by Type (2021-2032)
- 7.2 Europe CAR-T Therapy for Hematological Cancer Consumption Value by Application (2021-2032)
- 7.3 Europe CAR-T Therapy for Hematological Cancer Market Size by Country
- 7.3.1 Europe CAR-T Therapy for Hematological Cancer Consumption Value by Country (2021-2032)
- 7.3.2 Germany CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 7.3.3 France CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 7.3.5 Russia CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 7.3.6 Italy CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
8 Asia-Pacific
- 8.1 Asia-Pacific CAR-T Therapy for Hematological Cancer Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific CAR-T Therapy for Hematological Cancer Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size by Region
- 8.3.1 Asia-Pacific CAR-T Therapy for Hematological Cancer Consumption Value by Region (2021-2032)
- 8.3.2 China CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 8.3.3 Japan CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 8.3.4 South Korea CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 8.3.5 India CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 8.3.7 Australia CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
9 South America
- 9.1 South America CAR-T Therapy for Hematological Cancer Consumption Value by Type (2021-2032)
- 9.2 South America CAR-T Therapy for Hematological Cancer Consumption Value by Application (2021-2032)
- 9.3 South America CAR-T Therapy for Hematological Cancer Market Size by Country
- 9.3.1 South America CAR-T Therapy for Hematological Cancer Consumption Value by Country (2021-2032)
- 9.3.2 Brazil CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 9.3.3 Argentina CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
10 Middle East & Africa
- 10.1 Middle East & Africa CAR-T Therapy for Hematological Cancer Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa CAR-T Therapy for Hematological Cancer Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Country
- 10.3.1 Middle East & Africa CAR-T Therapy for Hematological Cancer Consumption Value by Country (2021-2032)
- 10.3.2 Turkey CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
- 10.3.4 UAE CAR-T Therapy for Hematological Cancer Market Size and Forecast (2021-2032)
11 Market Dynamics
- 11.1 CAR-T Therapy for Hematological Cancer Market Drivers
- 11.2 CAR-T Therapy for Hematological Cancer Market Restraints
- 11.3 CAR-T Therapy for Hematological Cancer Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 CAR-T Therapy for Hematological Cancer Industry Chain
- 12.2 CAR-T Therapy for Hematological Cancer Upstream Analysis
- 12.3 CAR-T Therapy for Hematological Cancer Midstream Analysis
- 12.4 CAR-T Therapy for Hematological Cancer Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on CAR-T Therapy for Hematological Cancer. Industry analysis & Market Report on CAR-T Therapy for Hematological Cancer is a syndicated market report, published as Global CAR-T Therapy for Hematological Cancer Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of CAR-T Therapy for Hematological Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
